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Summary
Vitamin D–dependent rickets type I (VDDR-I), also
known as pseudo–vitamin D–deficiency rickets, appears
to result from deficiency of renal vitamin D 1a-hydrox-
ylase activity. Prior work has shown that the affected
gene lies on 12q13.3. We recently cloned the cDNA and
gene for this enzyme, mitochondrial P450c1a, and we
and others have found mutations in its gene in a few
patients. To determine whether all patients with VDDR-
I have mutations in P450c1a, we have analyzed the
P450c1a gene in 19 individuals from 17 families rep-
resenting various ethnic groups. The whole gene was
PCR amplified and subjected to direct sequencing; can-
didate mutations were confirmed by repeat PCR of the
relevant exon from genomic DNA from the patients and
their parents. Microsatellite haplotyping with the mark-
ers D12S90, D12S305, and D12S104 was also done in
all families. All patients had P450c1a mutations on both
alleles. In the French Canadian population, among
whom VDDR-I is common, 9 of 10 alleles bore the hap-
lotype 4-7-1 and carried the mutation 958DG. This hap-
lotype and mutation were also seen in two other families
and are easily identified because the mutation ablates a
TaiI/MaeII site. Six families of widely divergent ethnic
backgrounds carried a 7-bp duplication in association
with four different microsatellite haplotypes, indicating
a mutational hot spot. We found 14 different mutations,
including 7 amino acid replacement mutations. When
these missense mutations were analyzed by expressing
the mutant enzyme in mouse Leydig MA-10 cells and
assaying 1a-hydroxylase activity, none retained detect-
able 1a-hydroxylase activity. These studies show that
most if not all patients with VDDR-I have severe mu-
tations in P450c1a, and hence the disease should be
referred to as “1a-hydroxylase deficiency.”
Received July 15, 1998; accepted September 25, 1998; electronically
published November 6, 1998.
Address for correspondence and reprints: Dr. Walter L. Miller, De-
partment of Pediatrics, Building MR-IV, Room 209, University of Cal-
ifornia, San Francisco, San Francisco, CA 94143-0978.
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6306-0016$02.00
Introduction
Vitamin D, either ingested in the diet or synthesized in
the skin, is biologically inert and must be converted to
its hormonally active form by a bioactivation pathway
(for reviews see Strewler and Rosenblatt 1995; Feldman
et al. 1996). Activation consists of an initial 25 hy-
droxylation by hepatic mitochondrial P450c25 (Su et al.
1990; Usui et al. 1990) to produce 25-hydroxyvitamin
D (25OHD), which is largely inactive but is found abun-
dantly in blood at ∼107 M. The rate-limiting, hormon-
ally regulated, biologically activating step is renal
1a-hydroxylation of 25OHD to 1,25 dihydroxy-
vitamin D [1,25(OH)2D], which is found in blood at
vastly lower levels, ∼1010 M. This 1a-hydroxylation is
catalyzed by mitochondrial P450c1a (Fraser and Ko-
dicek 1970; Fu et al. 1997a) in renal-proximal con-
voluted tubules (Brunette et al. 1978; Kawashima et
al. 1981); another mitochondrial enzyme, P450c24
(Ohyama et al. 1991; Chen et al. 1993), catalyzes 24-
hydroxylation, which may initiate an inactivation
pathway.
Vitamin D–dependent rickets type I (VDDR-I), or
pseudo–vitamin D–deficiency rickets (MIM 264700), is
characterized by failure to thrive, muscle weakness,
hypocalcemia, secondary hyperparathyroidism, and the
bony changes of rickets (Fraser et al. 1973; Scriver et
al. 1978; Delvin et al. 1981). Affected subjects have nor-
mal concentrations of 25OHD and very low concentra-
tions of 1,25(OH)2D. This disease, which can be treated
with physiological replacement doses of 1,25(OH)2D,
can be caused by mutations in the gene encoding
P450c1a, the renal and keratinocyte 1a-hydroxylase (Fu
et al. 1997a). This gene has been fully sequenced (Na-
tional Center for Biotechnology Information accession
number AF 027152) and exists in a single copy, con-
sisting of nine exons spanning only 5 kb (Fu et al. 1997b;
Monkawa et al. 1997; Kitanaka et al. 1998). Linkage
analysis of the disease phenotype (Labuda et al. 1990),
gene localization via human/rodent somatic-cell hybrids
(Fu et al. 1997b), and FISH (St.-Arnaud et al. 1997;
Kitanaka et al. 1998) have shown that the gene maps
to 12q13.3, a finding consistent with the autosomal re-
cessive inheritance of 1a-hydroxylase deficiency.
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Table 1
Oligonucleotide Primers Used for PCR Amplification and Sequencing of the P450c1a Gene
Exon Sense Primer Antisense Primer
Size
(bp)
1 5′-CCTCACCCAAAGGTTAAATAG-3′ (61) 5′-CATTTGCTCTGCACTAGTCAG-3′ (64) 364
2 5′-TGGGCACAGGTCAAGCTGAAA-3′ (48) 5′-GATAGTTTCGGGACCCGCAGC-3’ (48) 333
3 5′-CGCGCTCCTTCACTGCAGCCA-3′ (55) 5′-AGGGGGCGCCGTCAGGGTTCC-3′ (54) 357
4 5′-CAGAGCTGGGCAGGCGTCGGG-3′ (52) 5′-GAAGGCACGTGAATACCTCGC-3′ (52) 348
5 5′-AGGCACAGGTCGAGGTGGAAA-3′ (60) 5′-TGGAGCCGGAGTCTGCGGAGG-3′ (43) 320
6 5′-TCTGCACCCTCTGCTGGGTTC-3′ (39) 5′-CCCTGCTTCCATCCACTAGTT-3′ (57) 312
7 5′-GAAGTTGGAAACAATGAGAAG-3′ (56) 5′-AGAGTGTTTGAGAACAGGGTt-3′ (56) 235
8 5′-TGCCTGCCCTATTCTGAGCCC-3′ (32) 5′-CACAACTTTAGAGGGTTAGGG-3′ (41) 315
9 5′-ACCAATTGGATTACCAATGAA-3′ (53) 5′-GTATACCTTGGTCTTGTGCCT-3′ (61) 272
NOTE.—Sense and antisense primers were in flanking or intronic DNA; the minimum distance between each
primer and the corresponding exon is given in parentheses following the primer sequence. When an individual
exon was amplified, the resulting PCR fragment had the size indicated in the far right column.
VDDR-I is rare in most populations, but it is partic-
ularly common among French Canadians, having an
apparent carrier rate of 1/26 in the Charlevoix–
Saguenay–Lac Saint Jean area of Que´bec (De Braekeleer
1991). Microsatellite analysis mapped the gene proximal
to D12S312 and distal to (D12S305, D12S104) (Labuda
et al. 1996). Analysis of 32 families, including 20 from
Que´bec and 5 from eastern Canada, suggested (a) that
a haplotype analysis of three markers—D12S90,
D12S305, and D12S104—could distinguish the allelic
contributions of various founder populations and (b)
that the Charlevoix French Canadian subjects and the
eastern Canadian (Acadian) subjects derived from in-
dependent founder events (Labuda et al. 1996).
After the publication of our initial finding that
P450c1a mutations can cause this disease (Fu et al.
1997a), others confirmed and expanded this observation
in four Japanese families (Kitanaka et al. 1998), but no
extensive study of multiple ethnic groups has appeared.
We have developed a rapid PCR–based approach to an-
alyzing mutations in the P450c1a gene. Using this pro-
cedure, we describe 12 new mutations in 17 families
from eight ethnic groups, identify the common French
Canadian (Charlevoix) mutation and another common
mutation, correlate these with the microsatellite haplo-
typing, and provide a rapid RFLP–based diagnostic for
the Charlevoix mutation.
Material and Methods
DNA Preparation and PCR
Using reagents from Promega, we prepared genomic
DNA from whole blood by salt deproteination of nu-
cleated blood cells followed by alcohol precipitation,
as described by Miller et al. (1988). The sense primer
5′-CACAGATCTCTCAGGAGGAGGGATTGGCTG-3′
was synthesized corresponding to bases 76 to 47 of
the P450c1a gene (Fu et al. 1997b), except that the two
underlined T’s differed from the gene, so as to create
a BglII cleavage site (AGATCT). The antisense primer
5′-GGAATTCAGATAGGCATTAGGGGAAGATGTA-
3′ was synthesized antisense to bases 4034 to 4059, plus
six 5′ bases, to create an EcoRI cleavage site (GAATTC).
The PCR reaction included 200 ng of genomic DNA and
100 ng of each primer in 100 ml of 67 mM Tris-HCl
pH 8.8, 16 mM (NH4)2SO4, 0.01% Tween-20, 2.5 mM
MgCl2, 0.2 mM each dNTP, and two units of a 20:1
mixture ofTaq and pfuDNA polymerases that has better
long-range processivity and higher fidelity than either
polymerase alone (Cheng et al. 1994). PCR amplification
was done with a program of 95C for 3 min followed
by 40 cycles at 95C for 1 min and 65C for 5 min on
a TC1 thermal cycler (Perkin-Elmer).
Cloning and Gene Sequencing
The 4149-bp PCR product was either sequenced
directly without cloning or cleaved with BglII and
EcoRI, subcloned into BamHI/EcoRI-cleaved vector
pGEM3Zf (Promega), and prepared from single col-
onies. Each exon was sequenced on both strands with
the primers shown in table 1 on an ABI Prism
automated fluorescence sequencer. Putative mutations
found on initial sequencing were checked twice by PCR
amplification and sequencing of the affected exon di-
rectly from the genomic DNA of the patients and their
parents, bypassing the 4-kb PCR.
Microsatellite Haplotype Analysis
PCR primers for the microsatellite markers D12S90,
D12S305, and D12S104 (Labuda et al. 1996) were syn-
thesized according to sequences obtained from the
Whitehead Institute web page. The sense primer for each
marker was end labeled with g[32P]-ATP (Amersham)
and T4 polynucleotide kinase (New England Biolabs).
The PCR reactions included 50 ng of genomic DNA, 5
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Table 2
Clinical Data in Patients with 1a-Hydroxylase Deficiency
Patient
Age at
Evaluation
Ca
[8.5–10.5]
(mg/dl)
P
[4–6]
(mg/dl)
Alk Phos
[150–250]
(IU/L)
PTH
[10–60]
( pg/ml)
25OHD
[10–60]
(ng/ml]
1,25(OH)2D
[20–60]
(pg/ml)
1aa 9.8 years 9.6 3.8 275 265b 30 11
1ba 7.8 years 9.8 3.8 356 300b 59 16
2 13 mo 6.2 3.7 1042 171 103 55c
3 10 years 6.5 3.6 625 “High” 37 8
4 18 mo 6.1 2.5 1720 980b 30 !2
5a 23 mo 5.5 4.7 1900 ) ) )
5b 6 mo “Low normal” ) 600 ) ) )
6a 18 mo !8.0 2.6 1300 ) 256 !20
7 11 mo 6.1 2.8 1958 2231 40 9
8d 12.5 years 7.4 3.3 920 524b 24 15
9d 8 years 8.4 2.0 3120 “High” 124 4
10 11.5 years 7.6 5.5 1730 ) 304 44
11a 24 mo 5.8 3.0 1005 90 ) !17
12 12 mo 7.2 2.8 1515 101 58 !5
13 16 mo 5.7 4.4 1183 472 45 19
14 10.2 years 8.0 2.9 1113 945b 46 !5
15 9 mo 6.8 3.8 1660 ) 45 !10
16 16 mo 8.1 2.2 3542 862 86 10
17e 13 mo 7.4 1.5 1880 377 110 !12
NOTE.—Values in brackets denote normal pediatric ranges.
a Had been receiving treatment since infancy; all medications were held for 11 week.
b C-terminal assays (normal range !330 ng/ml).
c Receiving calcitriol 0.25 mg/day.
d Described by Pronicka et al. (1992).
e Described by Fu et al. (1997a).
pmol of each primer, and 0.5 units of Taq polymerase
(Perkin Elmer) in 20 ml of 20 mM Tris-HCl pH 8.4, 50
mM KCl, 1.5 mM MgCl2, and 50 mM each dNTP, with
30 cycles at 94C for 45 s, 55C for 45 s, and 72C for
45 s. The PCR products were displayed by electropho-
resis on a 6% polyacrylamide sequencing gel, and the
data were analyzed on a Storm 860 Phosphorimager
(Molecular Dynamics). Unknown alleles were assigned
by comparison with amplified patient DNA containing
previously identified alleles (Labuda et al. 1996) and by
comparison with an M13 sequencing ladder. Alleles were
designated as described by Labuda et al. (1996). All
analyses were done by one of us (S.M.B.), including con-
firmation of several previously assigned haplotypes (La-
buda et al. 1996).
Site-Directed Mutagenesis and cDNA Expression
Identified mutations causing missense mutations were
recreated by PCR-based oligonucleotide-mediated mu-
tagenesis of our human P450c1a cDNA (National Cen-
ter for Biotechnology Information accession number AF
020192) expression vector in pcDNA3 (Fu et al. 1997a),
as described by Braman et al. (1996), using pfu DNA
polymerase and selective digestion of wild-type parent
plasmids with DpnI. After confirming the mutations by
sequencing, we transfected MA-10 cells at 50%–60%
confluence with 2 mg plasmid DNA/ml using adenovirus-
mediated transfection (Forsayeth and Garcia 1994), as
described (Fu et al. 1997a). The cells were transferred
to serum-free medium and incubated with 25-OHD3;
then the cells and medium were extracted with aceton-
itrite, and the 1,25(OH)2D was determined by duplicate
radio-receptor assay following C-18 and silica SepPack
chromatography, all exactly as described (Reinhardt et
al. 1984; Fu et al. 1997a).
Amino Acid Sequence Alignments
Sequences were aligned on the basis of secondary
structures rather than linear amino acid sequence align-
ments. The structural alignments of P450cam, P450trp,
and P450eryF were determined by combining the align-
ments of Hasemann et al. (1994, 1995) and of Cupp-
Vickery and Poulos (1995). The presumed locations of
P450c1a secondary structures were determined as de-
scribed (Kneller et al. 1990), using an algorithm avail-
able from the web site of the University of California,
San Francisco (UCSF), Department of Pharmaceutical
Chemistry. Our previous alignment (Fu et al. 1997b) of
the P450c1a sequence with P450c25 (CYP27) and align-
ment of rabbit CYP27 with P450cam and P450trp (Has-
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Table 3
Genetic Data in Patients with 1a-Hydroxylase Deficiency
Patient Ethnicity
Microsatellite
Haplotype
(Maternal/
Paternal)
Mutationsa
(Maternal/Paternal)
1a Filipino 4-1-1/9-6-2 T409I/7bpdup
1b Filipino 4-1-1/9-6-2 T409I/7bpdup
2 White-USA 9-5-2/4-7-1 R389H/958DG
3 French Canadian 4-7-1/9-1-2 958DG/R389H
4 French Canadian 4-7-1/4-7-1 958DG/958DG
5a French Canadian 4-7-1/4-7-1 958DG/958DG
5b French Canadian 4-7-1/4-7-1 958DG/958DG
6 French Canadian 4-7-1/4-7-1 958DG/958DG
7 White-USA 4-7-1/4-7-1 958DG/958DG
8 Polish 6-7-2/4-1-2 P497R/E189L
9 Polish 9-5-2/9-5-2 W241X/W241X
10 Polish 9-7-2/9-7-2 7bpdup/7bpdup
11 Chinese 9-7-2/9-5-2 7bpdup/Q65H
12 French Canadian 4-7-1/4-7-1 958DG/958DG
13 White-USA 4-1-1/9-3-3 2bpdup/7bpdup
14 Black-USA 4-5-1/6-6-1 R429P/7bpdup
15 Haitian 4-7-2/4-7-2 R453C/R453C
16 Hispanic 4-1-1/9-7-2 212DG/7bpdup
17 White-USA ) 1921DG, 1984Dcb
a Amino acid replacement mutations are indicated according to co-
don number; nucleotide deletions are numbered from the transcrip-
tional start site; 7bpdup refers to the insertion of an additional CCC
ACC C sequence in codons 438–442.
b Parental alleles unavailable for assignment.
emann et al. 1995) facilitate manual alignment using the
C-terminal region of the I-helix and the EXXR motif in
the K-helix as initial landmarks.
Results
Clinical Findings in 1a-Hydroxylase Deficiency
Blood or DNA samples were obtained from 19 pa-
tients in whom the diagnosis of 1a-hydroxylase defi-
ciency had been made. The patients are presently 1–35
years old and represent 17 presumably unrelated families
from various ethnic backgrounds; 2 families had 2 af-
fected siblings. Patient 17 has been reported by us pre-
viously (Fu et al. 1997a) and is included for complete-
ness. There were 11 females and 8 males, consistent with
the autosomal recessive nature of the disease. All of the
patients were healthy at birth but came to medical at-
tention within the first 24 months of life, most com-
monly because of growth retardation, slowing of
growth, or poor gross motor development. Some infants
had irritability or pain when held, developed pneumo-
nia, or had seizures. Physical findings included enlarge-
ment of the costochondral junctions of the ribs, enlarge-
ment of the wrists and ankles, genu varus, and, in some
children, hypotonia or frontal bossing. All patients had
radiographic signs of active rickets. Laboratory data
revealed hypocalcemia, hypophosphatemia, increased
serum concentrations of alkaline phosphatase and
parathyroid hormone (PTH), normal concentrations
of 25OHD, and greatly reduced concentrations of
1,25(OH)2D. The available clinical data at the time of
presentation for each patient are presented in table 2.
All patients were treated with either 1,25(OH)2D3 or
1aOHD3, either initially at the time of diagnosis or after
failure of treatment with vitamin D2. Currently, all pa-
tients are receiving treatment with 1,25(OH)2D3, have
no clinical or radiographic signs of rickets, and have
normal serum levels of calcium and phosphorus. PTH
concentration is normal in those in whom it has been
measured.
Microsatellite Haplotyping
In a previous study, the markers D12S90, D12S305,
and D12S104 showed complete linkage disequilibrium
with 1a-hydroxylase deficiency, but other markers on
chromosome 12 showed some recombination (Labuda
et al. (1996). These three markers are close to the gene
for P450c1a, but the number of alleles is limited: seven
for D12S90, five for D12S305, and only three for
D12S104, so that use of these three markers can describe
only 105 unique microsatellite haplotypes. Among the
16 families (31 alleles) that we haplotyped, only 10 mi-
crosatellite haplotypes were found (table 3). The 4-7-1
haplotype, previously associated with the founder effect
in the Charlevoix–Saguenay–Lac Saint Jean area of Que´-
bec (“Charlevoix”) (Labuda et al. 1996), was found in
9 of 10 French Canadian alleles (families 3–6 and 12),
as well as in 2 of 3 alleles of families 2 and 7. Hetero-
zygous patient 2, from the southeastern United States,
had a French surname. Patient 7, from the Pacific North-
west, was the product of a consanguineous union; the
patient had been adopted, and the ethnic origins of the
biological parents were unknown. The 4-1-1 haplotype
was found in three distinct ethnic groups: Filipino (fam-
ily 1), American Caucasian (family 13), and Hispanic
(family 16), and the 9-7-2 haplotype was similarly
widely distributed among Polish (family 10), Chinese
(family 11), and Hispanic (family 16) individuals. Thus,
only the 4-7-1 Charlevoix haplotype appeared to be
strongly associated with one ethnic group.
Mutation Analysis
The use of a mixture of thermostable DNA polymer-
ases with proofreading subunits permitted us to amplify
the entire 4.2-kb gene for P450c1a as a single fragment.
Direct sequencing on both strands of all nine exons of
this PCR product without prior subcloning generally re-
quired several 4.2-kb PCR reactions to yield enough ma-
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Figure 1 Genetic diagnosis of the 958DG (Charlevoix) mutation.
Genomic DNA was amplified with oligonucleotides corresponding to
bases 52–81 (sense) and bases 1612–1638 (antisense) and was digested
withTaiI. The homozygously affected patient has only a 1458-bp band,
the normal control has only the 778-bp and 680-bp bands, and the
obligately heterozygous parent of the patient has all three bands.
Markers: Gibco 1-kb ladder.
Figure 2 Microsatellite analysis. The microsatellite D12S305
was PCR amplified from DNA from patients 1a and 10 and was
compared with a known DNA sequencing ladder to determine the
exact sizes of the alleles. The PCR products are 121 bp and 119 bp,
respectively, proving that the 9-6-2 haplotype of family 1 is different
from the 9-7-2 haplotype of family 10.
terial, but the resulting error rate was only ∼1/12,000
bases, permitting the processing of several samples per
week.
Mutations were found in all patients, but these did
not always correlate well with the microsatellite hap-
lotype analysis (table 3). The 4-7-1 Charlevoix haplo-
type was associated with the deletion of guanine 958,
as numbered from the gene’s transcriptional start site
(Fu et al. 1997b). This 958DG mutation lies in codon
88, within the context 5′ ACGT 3′, which is the rec-
ognition sequence for the endonucleases TaiI and MaeII;
the Charlevoix mutation destroys this site, permitting
rapid diagnosis. There are three additional TaiI/MaeII
sites in exon 3; however, PCR with the sense oligonu-
cleotide 5′-ATGACCCAGACCCTCAAGTACGCCTC-
CAGA-3′ (bases 52–81, codons 1–10) and the antisense
oligonucleotide 5′-GAGCGGGGCCAGGAGACTGC-
GGAGCCT-3′ (bases 1612–1638, codons 136–144) gen-
erates a 1,458-bp fragment that contains only the rele-
vant TaiI/MaeII site. Digestion of the normal sequence
yields fragments of 778 and 680 bp, digestion of the
mutant sequence yields only the 1,458-bp fragment, and
DNA from heterozygotes has all three fragments, thus
providing rapid prenatal or other diagnosis (fig. 1).
Thus, the 4-7-1 haplotype was associated with 958DG
in all families tested.
The gene for P450c1a contains the duplicated se-
quence 5′-CCCACCC CCCACCC-3′ in exon 8, encoding
residues 438–442 (Pro-Thr-Pro-His-Pro). In six families
we found three rather than two copies of this 7-bp se-
quence, which alters the downstream reading frame and
creates a premature TGA stop signal at codon 446. As
this is upstream from the heme thiolate cystine at codon
455, the resulting truncated protein is devoid of activity.
This 7-bp duplication was found in all alleles carrying
the haplotype 9-7-2 (families 10, 11, and 16) but was
also associated with the haplotypes 9-6-2 (family 1), 9-
3-3 (family 13), and 6-6-1 (family 14). The 9-7-2 and
9-6-2 haplotypes are indeed distinct, as shown by the
analysis of both D12S305 microsatellite haplotypes on
a single gel (fig. 2); however, the difference could also
be due to a microsatellite mutation. Furthermore, these
families were of Filipino, Polish, Chinese, white, black,
and Hispanic ancestry. The 7-bp duplication was asso-
ciated with the 9-7-2 haplotype in families of Polish,
Chinese, and Hispanic ancestry, while the possibly re-
lated 9-6-2 haplotype was in a Filipino family. It is not
clear why the 9-7-2 haplotype and the 7-bp duplication
are associated in such divergent populations, but it
should be noted that the Ge´ne´thon data indicate that
this is a very common (10.6%) haplotype among Cau-
casians (Gyapay et al. 1994). Thus, the ethnic and hap-
lotype diversity associated with the 7-bp duplication sug-
gests that it has arisen by several independent de novo
events and that the correlation between the microsatellite
haplotypes and the mutations may be limited.
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Table 4
Activity of the P450c1a Mutants
Construct
1,25(OH)2D
(pg/plate)a
Vector 65
Q65H 68
E189L 85
R389H 45
T409I 52
R429P 58
R435C 65
P497R 60
Wild-type 1,530
a Detection limit, 8 pg/plate.
Patient 13 was a compound heterozygote for the 7-
bp duplication and for a 2-bp duplication (underlined)
in the same region—5′-CCCACCCCCCACACCC-3′—
again causing a frameshift and further suggesting that
this area is a mutational hot spot. The mutation R389H
was associated with two haplotypes, 9-1-2 in family 3
and 9-5-2 in family 2, and this 9-5-2 haplotype was
associated with W241X in family 9. Thus, with the ex-
ception of the consistent correlation between 4-7-1 and
958DG, the haplotypes did not predict the mutations.
Other mutations and haplotypes were confined to in-
dividual families. Patient 8 was a compound heterozy-
gote for two haplotypes (6-7-2 and 4-1-2) and two mu-
tations (P497R and E189L) seen in no other family.
Patient 15 was homozygous for the mutation R453C
and for the haplotype 4-7-2.
Activities of the Mutants
Each of the amino acid replacement mutations iden-
tified was recreated in a P450c1a expression vector by
oligonucleotide-mediated site-directed mutagenesis, and
its structure confirmed by complete sequencing of the
mutant vector. These vectors were then transfected into
mouse testicular Leydig MA-10 cells and assayed for 1a-
hydroxylase activity. Like all mitochondrial P450 en-
zymes, P450c1a requires electron transfer from ferre-
doxin reductase and ferredoxin (Miller 1988). MA-10
cells contain the type I mitochondrial enzyme P450scc,
which converts large amounts of cholesterol to preg-
nenolone and hence abundantly express the electron
transport proteins ferredoxin and ferredoxin reductase.
Expression of mitochondrial P450 enzymes in MA-10
cells yields 1,000-fold more activity than expression in
monkey kidney COS-1 cells, which have small amounts
of these proteins (Fardella et al. 1996), so that MA-10
cells provide a very sensitive assay system for the 1a-
hydroxylase activity of P450c1a. As shown in table 4,
none of these mutants yields significantly more activity
than the low endogenous activity of the MA-10 cells
(vector control), which we described previously (Fu et
al. 1997a).
Discussion
The recent cloning of the cDNA and gene for human
P450c1a showed that vitamin D 1a-hydroxylase activity
was catalyzed solely by this enzyme and that mutation
of the corresponding gene could cause VDDR-I (Fu et
al. 1997a, 1997b; Kitanaka et al. 1998). We have now
surveyed 19 patients from 17 kindreds with this disease
and have found that all patients are homozygous or com-
pound heterozygous for mutations in P450c1a that de-
stroy all detectable 1a-hydroxylase activity. Thus, 1a-
hydroxylase deficiency, caused by mutations in the gene
encoding P450c1a, appears to be the only cause of this
disease; hence, it is appropriate that the term “1a-hy-
droxylase deficiency” should now supersede the obsolete
terms “vitamin D–dependent rickets, type I” and
“pseudo–vitamin D–deficiency rickets.”
P450c1a is a typical mitochondrial (class I) cyto-
chrome P450. There are only four other known eukar-
yotic members of this class of enzyme: (1) P450scc, the
cholesterol side-chain cleavage enzyme (Chung et al.
1986; Morohashi et al. 1987); (2) P450c11b, the steroid
11b-hydroxylase, and its isozyme P450c11AS, the al-
dosterone synthetase (Mornet et al. 1989); (3) P450c24,
the vitamin D 24-hydroxylase (Chen et al. 1993); and
(4) P450c25 (also termed “P450c27”), which catalyzes
vitamin D 25-hydroxylation and the 26- or 27-hydrox-
ylation of bile acids (Su et al. 1990; Cali and Russell
1991). To promote catalysis, all of these mitochondrial
P450 enzymes require electrons from NADPH that are
delivered to the P450 moiety through the intermediacy
of ferredoxin (Chang et al. 1988; Picado-Leonard et al.
1988) and ferredoxin reductase (Solish et al. 1988; Lin
et al. 1990). The tissue distribution of expression of these
P450s is highly specific, but ferredoxin (Picado-Leonard
et al. 1988) and ferredoxin reductase (Brentano et al.
1992) are found in all human tissues examined, albeit
in highly varying quantities; thus, there may be other
mitochondrial P450 enzymes that remain to be char-
acterized. It may be noteworthy that all mitochondrial
P450 enzymes characterized to date catalyze biosyn-
thetic processes, in contrast to the many hepatic micro-
somal (class II) P450 enzymes, which are primarily in-
volved in the catabolism of xenobiotics.
Like mitochondrial P450 enzymes, most bacterial
P450s are also class I, receiving electrons from a ferre-
doxin and a ferredoxin reductase. The structures of sev-
eral of these soluble bacterial P450 enzymes have been
determined by X-ray crystallography, including the class
I enzymes P450cam (Poulos et al. 1987), P450terp (Has-
emann et al. 1994), and P450eryF (Cupp-Vickery and
Poulos 1995) and the class II enzyme P450BM-P (Rav-
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Figure 3 Alignment of the sequence of human P450c1a (top) with the sequences of the crystallographically solved bacterial class I P450
proteins P450cam, P450trp, and P450eryF. The names of the various a-helices and b-sheets are given below, with the a-helices highlighted in
boldface and the b-sheets underlined. The locations of the “meander” and the Cys-pocket are also shown. The locations of the amino acid
replacement mutations identified in P450c1a are shown above its sequence with downward-pointing arrows.
ichandran et al. 1993). Comparisons of the structures
of these enzymes show remarkable conservation of their
topology and their tertiary structures, despite low amino
acid sequence identity (Hasemann et al. 1995). We
aligned the sequence of P450c1a with the class I bac-
terial P450 enzymes on the basis of regions of predicted
secondary structure rather than amino acid sequence
identity (fig. 3). This permits a preliminary assignment
of the locations of the amino acid replacement mutations
we found in P450c1a. The mutation Q65H is in a-helix
A′, T409I is in strand 3 of b-sheet 1, and R389H is in
strand 4 of b-sheet 1. Although these mutations are dis-
tant from one another in terms of their amino acid num-
bers, they lie in the clustered b-sheet domain that inter-
acts with the inner mitochondrial membrane and define
the substrate entry channel. While it is not yet possible
to define the exact lesion caused by each of these mu-
tations, their locations suggest that they are likely to be
conformational mutants that disrupt the ability of the
enzyme to bind substrate rather than mutants that dis-
rupt the catalytic site or the redox partner binding site.
The mutant E189L lies in the E-helix and would disrupt
the four-helix bundle consisting of the D, E, I, and L
helices, and thus it would cause a significant disruption
in the P450 structure. The mutant R429P inserts a pro-
line at the junction of the K′ helix and the meander,
changing the direction of the carbon backbone and
grossly disrupting the meander. The mutant R453C,
which is only two residues away from the thiolate cys-
teine 455, disrupts a salt bridge that interacts with the
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heme proprionate, much like the corresponding R440C
mutation of P450c17, which causes complete 17a-hy-
droxylase deficiency (Fardella et al. 1994), and like the
R435C mutation in P450arom, which causes complete
aromatase deficiency (Conte et al. 1994). Finally, the
P497R mutant lies near strand 3 of b-sheet 3, which
participates in defining the top of the substrate-binding
pocket; the directional change in the a-carbon backbone
resulting from insertion of a proline probably disrupts
substrate binding. Thus, each of the identified P450c1a
missense mutations is in a location predicted to disrupt
enzymatic activity, consistent with the experimental
demonstration that each lacks 1a-hydroxylase activity.
All of the frameshift and premature translation-arrest
mutants eliminate the heme-binding site of P450c1a and
hence cannot have 1a-hydroxylase activity. Further-
more, the seven missense mutations identified all lacked
significant 1a-hydroxylase activity when expressed in
transfected cells. However, despite this equivalent lack
of enzymatic activity, the patients had varying degrees
of severity of their clinical and laboratory findings. This
finding is probably associated with other factors that
can mitigate hypocalcemia, including early treatment
with varying doses of calcium and with other sterols that
may have a modest capacity to bind to the vitamin D
receptor. Thus, the severity of the P450c1a mutation
cannot be predicted from the clinical presentation of the
disease.
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